CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The SMARTER project aims to enhance the manufacturing of personalized cancer therapies using tumor-infiltrating lymphocytes by developing a smart bioprocessing platform. This innovative approach integrates real-time monitoring and adaptive control to improve efficiency and consistency in producing cell therapies for so…
Autologous immunotherapies have revolutionised cancer treatment providing impressive survival benefits in patients with blood cancers.
The next generation of personalised immunotherapies using tumour-infiltrating lymphocytes (TIL) aims to overcome efficacy limitations of CAR-T therapies in the treatment of solid tumours.
Lack of effective, fast, adaptive, controllable and scalable manufacturing process remains one of the critical bottlenecks for clinical adoption of such complex personalised cel…
GOTTFRIED WILHELM LEIBNIZ UNIVERSITAET HANNOVER
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
ACHILLES THERAPEUTICS UK LIMITED
United Kingdom, LONDON
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
United Kingdom, London
Type: Research institute
Activity type: Research Organisations
SME: Yes
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
